Genetic Technologies Ltd. (Nasdaq: GENE) entered an exclusive worldwide license agreement with the University of Melbourne to develop and commercialize a novel colorectal cancer risk assessment test. Shares of the molecular diagnostics company climbed 83 cents to close at $2.14.